Duncan Charles Cliff purchased $38K of VNDA
Duncan Charles Cliff purchased 10,000 shares of Vanda Pharmaceuticals Inc. (VNDA) at an average of $3.81 ($3.80–$3.82) across 3 trades over 2026-11-03 to 2026-11-05.
How this was made
The 30-second read
Why it matters
The director's purchase may be interpreted as a vote of confidence, potentially providing short‑term support for the stock. However, the transaction size is modest, limiting broader market impact.
Market read
A small insider purchase that may slightly buoy VNDA but is unlikely to drive significant price movement.
What to watch
If the director is accumulating ahead of upcoming clinical data or a partnership, the signal could be more material than the dollar amount suggests.
Background
Form 4 filings disclose insider trades and are considered primary disclosures. Vanda Pharmaceuticals is a U.S.-listed biotech company (ticker VNDA).
Ticker impact
Director Duncan Charles Cliff bought 10,000 shares of Vanda Pharmaceuticals for $38K, increasing his stake to 108,701 shares.
likely modest upward pressure as the market prices in the insider buying signal
Form 4 filings are primary source disclosures; a director purchase, even modest in size, can be viewed as a bullish signal, but the dollar amount is small relative to market cap.
Market effects
Minimal impact on the broader biotech sector; only a single insider transaction.
U.S. market only; no regional ripple effect.
Low; the filing is company‑specific.
Counterpoint
The purchase size is too small to move the stock; investors may ignore it.
Key entities
- DirectorDuncan Charles Cliff
Director of Vanda Pharmaceuticals who purchased 10,000 shares.
- CompanyVanda Pharmaceuticals Inc.
Biopharmaceutical company focused on developing treatments for serious diseases.
